IL10 and neoplasm: On the contrary, activated DCs are converted into tolerogenic phenotypes in the tumour microenvironment, where they promote Tregs (and not T‐effector cells), with the production of TGFβ and IL‐10 as an escape mechanism from immune clearance.1, 2